Patents by Inventor Steven L. Kunkel

Steven L. Kunkel has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • STEM CELL FACTOR INHIBITOR
    Publication number: 20220017613
    Abstract: Provided herein are methods, compositions, and uses relating to inhibitors of stem cell factor. For example, provided herein are antibodies targeting stem cell factor and methods for treating fibrotic and tissue remodeling diseases.
    Type: Application
    Filed: October 4, 2021
    Publication date: January 20, 2022
    Inventors: Nicholas W. Lukacs, Vladislav A. Dolgachev, Steven L. Kunkel, Cory M. Hogaboam, Sem H. Phan
  • THERAPEUTIC ANTIBODIES AND USES THEREOF
    Publication number: 20200255509
    Abstract: Provided herein are methods, compositions, and uses relating to inhibitors of stem cell factor. For example, provided herein are antibodies targeting stem cell factor and methods for treating fibrotic and tissue remodeling diseases.
    Type: Application
    Filed: December 10, 2019
    Publication date: August 13, 2020
    Inventors: NICHOLAS W. LUKACS, STEVEN L. KUNKEL, CORY HOGABOAM
  • Antibody targeting stem cell factor
    Patent number: 10501535
    Abstract: Provided herein are methods, compositions, and uses relating to inhibitors of stem cell factor. For example, provided herein are antibodies targeting stem cell factor and methods for treating fibrotic and tissue remodeling diseases.
    Type: Grant
    Filed: May 24, 2016
    Date of Patent: December 10, 2019
    Assignee: THE REGENTS OF THE UNIVERSITY OF MICHIGAN
    Inventors: Nicholas W. Lukacs, Steven L. Kunkel, Cory Hogaboam
  • STEM CELL FACTOR INHIBITOR
    Publication number: 20180030129
    Abstract: Provided herein are methods, compositions, and uses relating to inhibitors of stem cell factor. For example, provided herein are antibodies targeting stem cell factor and methods for treating fibrotic and tissue remodeling diseases.
    Type: Application
    Filed: October 12, 2017
    Publication date: February 1, 2018
    Inventors: Nicholas W. Lukacs, Vladislav A. Dolgachev, Steven L. Kunkel, Cory M. Hogaboam, Sem H. Phan
  • Stem cell factor inhibitor
    Patent number: 9790272
    Abstract: Provided herein are methods, compositions, and uses relating to inhibitors of stem cell factor. For example, provided herein are antibodies targeting stem cell factor and methods for treating fibrotic and tissue remodeling diseases.
    Type: Grant
    Filed: March 2, 2016
    Date of Patent: October 17, 2017
    Assignee: THE REGENTS OF THE UNIVERSITY OF MICHIGAN
    Inventors: Nicholas W. Lukacs, Vladislav A. Dolgachev, Steven L. Kunkel, Cory M. Hogaboam, Sem H. Phan
  • THERAPEUTIC ANTIBODIES AND USES THEREOF
    Publication number: 20160257742
    Abstract: Provided herein are methods, compositions, and uses relating to inhibitors of stem cell factor. For example, provided herein are antibodies targeting stem cell factor and methods for treating fibrotic and tissue remodeling diseases.
    Type: Application
    Filed: May 24, 2016
    Publication date: September 8, 2016
    Inventors: NICHOLAS W. LUKACS, STEVEN L. KUNKEL, CORY HOGABOAM
  • STEM CELL FACTOR INHIBITOR
    Publication number: 20160251423
    Abstract: Provided herein are methods, compositions, and uses relating to inhibitors of stem cell factor. For example, provided herein are antibodies targeting stem cell factor and methods for treating fibrotic and tissue remodeling diseases.
    Type: Application
    Filed: March 2, 2016
    Publication date: September 1, 2016
    Inventors: Nicholas W. Lukacs, Vladislav A. Dolgachev, Steven L. Kunkel, Cory M. Hogaboam, Sem H. Phan
  • Stem cell factor inhibitor
    Patent number: 9353178
    Abstract: Provided herein are methods, compositions, and uses relating to inhibitors of stem cell factor. For example, provided herein are antibodies targeting stem cell factor and methods for treating fibrotic and tissue remodeling diseases.
    Type: Grant
    Filed: July 9, 2013
    Date of Patent: May 31, 2016
    Assignee: THE REGENTS OF THE UNIVERSITY OF MICHIGAN
    Inventors: Nicholas W. Lukacs, Vladislav A. Dolgachev, Steven L. Kunkel, Cory M. Hogaboam, Sem H. Phan
  • THERAPEUTIC ANTIBODIES AND USES THEREOF
    Publication number: 20150018408
    Abstract: Provided herein are methods, compositions, and uses relating to inhibitors of stem cell factor. For example, provided herein are antibodies targeting stem cell factor and methods for treating fibrotic and tissue remodeling diseases.
    Type: Application
    Filed: July 10, 2014
    Publication date: January 15, 2015
    Inventors: Nicholas W. Lukacs, Steven L. Kunkel, Cory Hogaboam
  • Stem cell factor inhibitor
    Patent number: 8911729
    Abstract: Provided herein are methods, compositions, and uses relating to inhibitors of stem cell factor. For example, provided herein are antibodies targeting stem cell factor and methods for treating fibrotic and tissue remodeling diseases.
    Type: Grant
    Filed: January 10, 2012
    Date of Patent: December 16, 2014
    Assignee: The Regents of The University of Michigan
    Inventors: Nicholas W. Lukacs, Vladislav Dolgachev, Steven L. Kunkel, Cory M. Hogaboam, Sem H. Phan
  • Methods for treating pulmonary fibrosis
    Patent number: 8795668
    Abstract: Methods and compositions for the treatment of fibrosing diseases are described. More specifically, the invention demonstrates that inhibiting or otherwise decreasing the activity of CCL21 either alone or in combination with CCL19 will be effective in reducing the presence of fibrotic lesions and ameliorating the symptoms of fibrosing disorders.
    Type: Grant
    Filed: December 18, 2006
    Date of Patent: August 5, 2014
    Assignee: The Regents of the University of Michigan
    Inventors: Cory M. Hogaboam, Steven L. Kunkel
  • STEM CELL FACTOR INHIBITOR
    Publication number: 20140023651
    Abstract: Provided herein are methods, compositions, and uses relating to inhibitors of stem cell factor. For example, provided herein are antibodies targeting stem cell factor and methods for treating fibrotic and tissue remodeling diseases.
    Type: Application
    Filed: July 9, 2013
    Publication date: January 23, 2014
    Inventors: Nicholas W. Lukacs, Vladislav A. Dolgachev, Steven L. Kunkel, Cory M. Hogaboam, Sem H. Phan
  • STEM CELL FACTOR INHIBITOR
    Publication number: 20120321629
    Abstract: Provided herein are methods, compositions, and uses relating to inhibitors of stem cell factor. For example, provided herein are antibodies targeting stem cell factor and methods for treating fibrotic and tissue remodeling diseases.
    Type: Application
    Filed: January 10, 2012
    Publication date: December 20, 2012
    Applicant: THE REGENTS OF THE UNIVERSITY OF MICHIGAN
    Inventors: Nicholas W. Lukacs, Vladislav Dolgachev, Steven L. Kunkel, Cory M. Hogaboam, Sem H. Phan
  • BIOMARKERS PREDICTIVE OF PROGRESSION OF FIBROSIS
    Publication number: 20120282276
    Abstract: The present invention provides methods and kits for prognosing the progression of fibrosis in a subject having fibrosis, as well as methods for identifying a compound that can slow down the progression of fibrosis in a subject having fibrosis, methods of monitoring the effectiveness of a therapy in reducing the progression of fibrosis in a subject having fibrosis, methods of selecting a subject for participation in a clinical trial for the treatment of fibrosis, and methods for inhibiting progression of fibrosis in a cell or a subject having fibrosis. The methods are based on determining the level of Toll-like recepter 9 (TLR9).
    Type: Application
    Filed: November 4, 2010
    Publication date: November 8, 2012
    Applicants: THE REGENTS OF THE UNIVERSITY OF MICHIGAN, NOVARTIS AG
    Inventors: Cory Hogaboam, Steven L. Kunkel, Glenda Trujillo
  • Chimeric molecule for the treatment of th2-like cytokine mediated disorders
    Patent number: 7541040
    Abstract: The invention provides uses and methods for alleviating respiratory tract symptoms of allergy, asthma, and of viral, bacterial, fungal and parasitic infections by shifting inappropriate TH2 responses to TH1 responses by administering IL-13 receptor-targeted immunotoxins to the respiratory tract.
    Type: Grant
    Filed: February 28, 2002
    Date of Patent: June 2, 2009
    Assignees: The United States of America as represented by the Department of Health and Human Serivces, The Regents of the University of Michigan, Office of Technology Transfer
    Inventors: Raj K. Puri, Cory M. Hogaboam, Claudia Jakubzick, Steven L. Kunkel
  • Treatment of idiopathic pulmonary fibrosis using IP-10
    Patent number: 7265083
    Abstract: Disclosed are various discoveries concerning the angiogenic and angiostatic properties of the CXC chemokines, including the finding that the ELR motif controls the ability of these molecules to induce angiogenesis. Aspects of the invention include, for example, the identification of IP-10, MIG and certain IL-8 analogues as angiostatic agents, and their use in inhibiting angiogenesis in various systems.
    Type: Grant
    Filed: March 21, 2002
    Date of Patent: September 4, 2007
    Assignee: The Regents of The University of Michigan
    Inventors: Robert M. Strieter, Steven L. Kunkel
  • Treatment of liver disease and injury with CXC chemokines
    Patent number: 6719969
    Abstract: Disclosed is the surprising discovery that CXC chemokines function to induce rapid hepatocyte proliferation and liver regeneration after injury. The invention thus provides a range of compositions and methods for use in treating liver injury, including those suitable for treating acetaminophen overdose outside the therapeutic window for N-acetyl-cysteine treatment, and those that limit the hepatotoxic side-effects of gene therapy regimens.
    Type: Grant
    Filed: August 4, 2000
    Date of Patent: April 13, 2004
    Assignees: The Regents of The University of Michigan, University Court of The University of Edinburgh
    Inventors: Cory M. Hogaboam, Cynthia L. Bone-Larson, Kenneth J. Simpson, Nicholas W. Lukacs, Steven L. Kunkel, Lisa M. Colletti, Robert M. Strieter
  • Treatment of idiopathic pulmonary fibrosis using IP-10
    Publication number: 20030031645
    Abstract: Disclosed are various discoveries concerning the angiogenic and angiostatic properties of the CXC chemokines, including the finding that the ELR motif controls the ability of these molecules to induce angiogenesis. Aspects of the invention include, for example, the identification of IP-10, MIG and certain IL-8 analogues as angiostatic agents, and their use in inhibiting angiogenesis in various systems.
    Type: Application
    Filed: March 21, 2002
    Publication date: February 13, 2003
    Applicant: The Regents of The University of Michigan
    Inventors: Robert M. Strieter, Steven L. Kunkel
  • CXC chemokines as regulators of angiogenesis
    Patent number: 6491906
    Abstract: Disclosed are various discoveries concerning the angiogenic and angiostatic properties of the CXC chemokines, including the finding that the ELR motif controls the ability of these molecules to induce angiogenesis. Aspects of the invention include, for example, the identification of IP-10, MIG and certain IL-8 analogues as angiostatic agents, and their use in inhibiting angiogenesis in various systems.
    Type: Grant
    Filed: December 9, 1998
    Date of Patent: December 10, 2002
    Assignee: The Regents of the University of Michigan
    Inventors: Robert M. Strieter, Peter J. Polverini, Steven L. Kunkel
  • Method for treating asthma using SCF antibody
    Patent number: 5911988
    Abstract: This invention provides pharmaceutical compositions comprising anti-SCF antibodies for the reduction of eosinophila in the lungs of mammals. This invention also provides for methods of treating asthma and generating a murine model for asthma.
    Type: Grant
    Filed: August 18, 1997
    Date of Patent: June 15, 1999
    Assignees: Bayer Corporation, Univ. of Michigan
    Inventors: Elise Brownell, Nicholas Lukacs, Steven L. Kunkel, Robert M. Strieter